10/8/2019 6:47:00 AM
Lilly To Present New Data For Taltz, Olumiant And Mirikizumab At 28th Annual EADV Congress
10/7/2019 6:48:26 AM
Lilly's CYRAMZA Phase 3 Data In First-Line EGFR-Mutated NSCLC Published In The Lancet Oncology
10/3/2019 9:26:37 AM
Eli Lilly Reports Voluntary Delisting From Euronext Paris
10/3/2019 6:48:42 AM
Eli Lilly Says New Head-to-Head Data Show Taltz Superiority Versus TREMFYA
9/29/2019 11:59:26 AM
Lilly Announces Positive Registrational Data For Selpercatinib In Heavily Pretreated RET-Altered Thyroid Cancers
9/23/2019 6:48:19 AM
Lilly Announces Data From Number Of Studies Across Its Oncology Product Portfolio
9/20/2019 7:02:44 AM
AC Immune To Receive The First Milestone Payment Of CHF30 Mln From Lilly On Or Before Oct 7
9/20/2019 6:50:01 AM
Lilly: CHMP Issues Positive Opinion To Expand Trulicity Label To Include Results From REWIND CV Outcomes Trial
9/9/2019 3:25:23 AM
Lilly Presents Data From LIBRETTO-001 Clinical Trial
8/26/2019 6:47:15 AM
Eli Lilly: FDA Approves Taltz Injection 80 Mg/mL For Treatment Of Adults With Active Ankylosing Spondylitis
8/14/2019 6:47:45 AM
Lilly Launches Open Innovation Challenge To Help Transform IBD Care Through Digital Health
8/13/2019 6:54:56 AM
Lilly Says Taltz Met Primary And All Major Secondary Endpoints Up To Week 12 In Phase 4 IXORA-R Study